Glucagonoma

What is a Glucagonoma?

A glucagonoma is a rare pancreatic neuroendocrine tumor (NET) that secretes excessive glucagon, leading to a characteristic syndrome of diabetes, weight loss, and a distinctive skin rash called necrolytic migratory erythema (NME).

Key Facts:

  • Extremely Rare: ~1 in 20 million per year
  • Location: Pancreas (usually tail)
  • Size: Often large at diagnosis (>5 cm)
  • Malignant in 50-80%: Often metastatic at diagnosis (liver)
  • Peak Age: 50-70 years

How Does High Glucagon Cause Symptoms?

  • Glucagon: Hormone that raises blood sugar (opposes insulin)
  • Effects of Excess Glucagon:
    • Hyperglycemia → diabetes mellitus
    • Increased protein breakdown → weight loss, muscle wasting
    • Hypoaminoacidemia (low amino acids) → skin rash (necrolytic migratory erythema)
    • Increased lipolysis

Classic Triad ("The 4 D's"):

  1. Dermatitis (Necrolytic Migratory Erythema): Characteristic rash
  2. Diabetes Mellitus: Mild diabetes
  3. Deep Vein Thrombosis (DVT): Blood clots
  4. Depression, Weight Loss (Decline)

Symptoms:

1. Necrolytic Migratory Erythema (NME) - PATHOGNOMONIC (67-90%):

  • Appearance: Red, blistering rash → crusting, scaling, central healing with hyperpigmentation
  • Distribution: Perineum, groin, buttocks, lower abdomen, legs, face (perioralmost characteristic)
  • Cyclical: Lesions come and go, migrate
  • Painful, Itchy
  • Often mistaken for eczema, psoriasis, or fungal infection initially

2. Diabetes Mellitus (80-90%):

  • Usually mild (fasting glucose 120-200 mg/dL)
  • Easy to control

3. Weight Loss (70-90%):

  • Severe, progressive
  • Muscle wasting, cachexia

4. Thromboembolic Events (20-50%):

  • Deep vein thrombosis (DVT), pulmonary embolism (PE)
  • Increased clotting risk from tumor

5. Other Symptoms:

  • Diarrhea (15-30%)
  • Glossitis, Cheilitis: Inflammation of tongue, lips
  • Brittle Nails
  • Depression, Psychiatric Symptoms
  • Normocytic Normochromic Anemia

Diagnosis:

1. Serum Glucagon:

  • Normal: <50-100 pg/mL
  • Glucagonoma: Typically >1000 pg/mL (often 1000-10,000)
  • Markedly Elevated Glucagon is Diagnostic
  • Other Causes of Mild Elevation (100-500 pg/mL): Cirrhosis, chronic kidney disease, critical illness, starvation, glucocorticoids

2. Imaging (Localize Tumor, Assess Metastases):

  • CT or MRI Abdomen: Usually large pancreatic mass (>5 cm), liver metastases common
  • Gallium-68 DOTATATE PET/CT: Somatostatin receptor imaging

3. Skin Biopsy (NME):

  • Necrolysis in upper epidermis (hallmark finding)

4. Labs:

  • Fasting Glucose, HbA1c: Assess diabetes
  • Hypoaminoacidemia: Low plasma amino acids
  • Hypoalbuminemia, Anemia
  • Chromogranin A: Tumor marker (usually elevated)

Treatment:

1. Surgery (If Resectable):

  • Tumor Resection ± Metastasectomy: Curative if all tumor removed
  • Debulking Surgery: Even if metastatic—reduces hormone levels, improves symptoms (especially rash)
  • Note: Many patients have metastases (liver) at diagnosis

2. Somatostatin Analogs (SSAs) - FIRST-LINE for Symptom Control:

  • Octreotide (Sandostatin LAR®), Lanreotide (Somatuline®)
  • Effects:
    • Suppress glucagon secretion
    • Dramatic improvement in rash (often complete resolution)
    • Slow tumor growth
  • Dosing: Long-acting monthly injections

3. For Metastatic/Unresectable Disease:

  • Peptide Receptor Radionuclide Therapy (PRRT): Lutetium-177 DOTATATE (Lutathera®)
  • Everolimus (Afinitor®): mTOR inhibitor; slows tumor progression
  • Chemotherapy: Streptozocin-based regimens (relatively resistant to chemo)
  • Liver-Directed Therapies: Embolization, RFA, radioembolization for liver mets

4. Supportive/Symptomatic Treatment:

  • Nutritional Support:
    • High-protein diet
    • Amino acid supplementation (may improve rash)
    • Zinc supplementation
  • Diabetes Management: Usually easy to control with diet, metformin, or low-dose insulin
  • Anticoagulation: If DVT/PE develops (or prophylaxis if high risk)
  • Skin Care: Gentle cleansers, emollients for rash

Prognosis:

  • Slow-Growing Tumors: Even metastatic disease progresses slowly
  • 5-Year Survival:
    • Localized: 50-70%
    • Metastatic: 30-50%
  • Many patients live for years with metastatic disease
  • Symptom control (especially rash) greatly improves quality of life

Key Points:

  • Glucagonoma = rare pancreatic NET secreting excessive glucagon
  • Classic triad: Necrolytic migratory erythema (NME rash), diabetes, weight loss
  • NME is pathognomonic—red, blistering rash in groin, perineum, face
  • Diagnosis: Markedly elevated glucagon (>1000 pg/mL)
  • Treatment: Somatostatin analogs (octreotide, lanreotide) dramatically improve rash and symptoms